Edition:
United States

Celyad SA (CYAD.OQ)

CYAD.OQ on NASDAQ Stock Exchange Global Market

30.26USD
17 Jul 2018
Change (% chg)

$0.30 (+1.00%)
Prev Close
$29.96
Open
$29.51
Day's High
$30.26
Day's Low
$29.51
Volume
630
Avg. Vol
2,812
52-wk High
$64.00
52-wk Low
$25.55

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  CYAD.OQ Industry Sector
P/E (TTM): -- 214.90 33.15
EPS (TTM): -- -- --
ROI: -- -3.85 13.23
ROE: -- -5.38 15.27

BRIEF-Celyad Announces Pricing Of 47.3 Million Dollars Global Offering

* 1,276,087 ORDINARY SHARES IN EUROPE AND CERTAIN COUNTRIES OUTSIDE OF US AND CANADA IN CONCURRENT PRIVATE PLACEMENT AT PRICE OF EUR 22.29PER SHARE

May 17 2018

BRIEF-Celyad Says Grade 4 Adverse Events Occurred In Two THINK Trial Patients, Announces Q1 Business Update

* GRADE 4 SERIOUS ADVERSE EVENTS OCCURRED IN TWO PATIENTS OF CYAD-01 THINK TRIAL OUT OF 20 PATIENTS INCLUDED IN INTERIM SAFETY REPORT

May 16 2018

BRIEF-Celyad Successfully Administers CYAD-01 In First Patients In Shrink And Link Trials

* CELYAD SUCCESSFULLY ADMINISTERS CYAD-01 IN FIRST PATIENTS IN SHRINK AND LINK TRIALS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

May 03 2018

BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient

* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT

Apr 27 2018

BRIEF-Celyad To Present Updates On CYAD-01 At American Association For Cancer Research Annual Meeting

* CELYAD TO PRESENT UPDATES ON CYAD-01 AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING 2018

Mar 29 2018

Earnings vs. Estimates

No consensus analysis data available.